Successful treatment with rituximab and donor lymphocyte infusions for fulminant EBV-associated lymphoproliferative disorder that developed 14 years after unrelated BMT

Bone Marrow Transplant. 2011 Dec;46(12):1583-5. doi: 10.1038/bmt.2010.346. Epub 2011 Jan 31.

Authors

T Kawaguchi, S Tsukamoto, C Ohwada, M Takeuchi, T Muto, S Tanaka, S Sakai, Y Takeda, D Abe, E Sakaida, N Shimizu, K Yokote, T Iseki, K-I Imadome, C Nakaseko

PMID: 21278799
DOI: 10.1038/bmt.2010.346

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents / administration & dosage*
Blood Donors*
Bone Marrow Transplantation*
Epstein-Barr Virus Infections / therapy*
Herpesvirus 4, Human*
Humans
Lymphocyte Transfusion*
Lymphoproliferative Disorders / therapy*
Lymphoproliferative Disorders / virology
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
Rituximab
Time Factors
Transplantation, Homologous

Substances

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Rituximab